Communication on the risk of severe skin reactions with Dilatrend® (carvedilol)

Roche is informing healthcare professionals of newly emerged safety information for Dilatrend®. From a review of the cumulative data from the company's safety database, very rare cases of severe cutaneous adverse reactions such as toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) have been reported during treatment with carvedilol. The package insert for Dilatrend® will be updated with this important new safety information. Healthcare professionals are recommended to consider permanently discontinuing the use of Dilatrend® in patients who experience severe cutaneous adverse reactions possibly attributable to carvedilol. 
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under 'For Healthcare Professionals’.

Step 2: Click on 'Restricted Content' and log in via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’.

Step 4: Click on the Drug Alert tab to view the DHCPLs.